Sesen Bio Inc.

SESN
Bibb v. Sesen Bio, Inc. et al (Case No. 21-cv-07025), S.D.N.Y.

During trading hours on August 13, 2021, Sesen Bio announced that the U.S. Food and Drug Administration (FDA) declined to approve the Company’s Biologics License Application (BLA) for its bladder cancer treatment Vicineum. Shares of Sesen Bio stock had traded up over  50% since the market opened on August 9, 2021 after the Company announced second quarter 2021 earnings.  

On this news shares of Sesen Bio stock fell 75% in intraday trading.

Lead Plaintiff deadline
October 18, 2021
class period
December 21, 2020
to
August 17, 2021
Case Documents
No documents available. Contact us if you need a case document.